Volume 102, Issue 10 , Pages 1394-1398, 15 November 2008
Association Between Renal Function and Circulating Levels of Natriuretic Peptides (from the Dallas Heart Study)
The relations between renal function and circulating B-type natriuretic peptide (BNP) and the amino-terminal fragment of its prohormone (NT-pro-BNP) in the general population have not been fully elucidated. A total of 2,784 subjects from the Dallas Heart Study, a multiethnic population-based sample of Dallas County, Texas, residents, was studied. Detailed cardiac phenotyping, including magnetic resonance imaging and electron beam computed tomography, as well as measurements of NT-pro-BNP and BNP, were performed. Associations between estimated glomerular filtration rate (eGFR) and both NT-pro-BNP and BNP were evaluated using multivariable statistical analysis techniques. Median eGFR in this young, predominantly healthy population was 97 ml/min/1.73 m2 (interquartile range 84 to 112). Natriuretic peptide levels were not associated with renal function over the normal range of eGFR. Below a threshold eGFR of 90 ml/min/1.73 m2, both NT-pro-BNP and BNP increased in an exponential fashion with decreasing eGFR. These associations remained significant after adjustment for multiple potential confounders (p <0.001 for all). For eGFR <90 ml/min/1.73 m2, the relative increase in NT-pro-BNP was twice as great as that for BNP for a given decrease in eGFR. In conclusion, a threshold effect regarding the association between renal function and natriuretic peptides was shown. With eGFR <90 ml/min/1.73 m2, both NT-pro-BNP and BNP were inversely and independently associated with renal function, with a greater magnitude of association with renal impairment noted for NT-pro-BNP.
To access this article, please choose from the options below
The Dallas Heart Study was supported by the Donald W. Reynolds Foundation, United States Public Health Service General Clinical Research Center Grant M01-RR00633 from the National Institutes of Health/National Center for Research Resources-Clinical Research, with support and reagents from Roche Diagnostics, Indianapolis, Indiana, and Biosite Inc., San Diego, California. Dr. de Lemos has received consulting income from Biosite, Roche Diagnostics, and Inverness Medical, Innovations, Inc., Waltham, Massachussets; Dr. McGuire has received consulting income from Biosite; and Dr. Drazner has received consulting income from Inverness Medical.
PII: S0002-9149(08)01233-2
doi:10.1016/j.amjcard.2008.07.018
© 2008 Elsevier Inc. All rights reserved.
Volume 102, Issue 10 , Pages 1394-1398, 15 November 2008
